Pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) are both deadly
cancers and they share many biological features besides their close anatomical location. …

Background Patients with initially unresectable colorectal cancer liver metastases might
qualify for local treatment with curative intent after reducing the tumour size by induction …

Background The aim of this nationwide cohort study was to examine the course of symptoms
and trajectories of health-related quality of life (HR-QoL) and psychological distress during …

PURPOSE DPYD-guided fluoropyrimidine dosing improves patient safety in carriers of
DPYD variant alleles. However, the impact on treatment outcome in these patients is largely …

Background Perihilar cholangiocarcinoma (pCCA) is a rare tumour that requires complex
multidisciplinary management. All known data are almost exclusively derived from expert …

Metastatic colorectal cancer (CRC) is a common cause of cancer-related mortality, of which
peritoneal metastases (PMs) have the worse outcome. Metastasis-specific markers may help …

Background Periampullary adenocarcinoma consists of pancreatic adenocarcinoma (PDAC),
distal cholangiocarcinoma (DC), ampullary cancer (AC), and duodenal adenocarcinoma (…

The added value of capecitabine to adjuvant gemcitabine monotherapy (GEM) in pancreatic
ductal adenocarcinoma (PDAC) was shown by the ESPAC‐4 trial. Real‐world data on the …

A bioanalytical assay for the new poly(ADP-ribose) polymerase-1 inhibitor olaparib in
combination with melphalan was developed and validated. For the quantitative assay, human …

Background Most data on the treatment and outcomes of intrahepatic cholangiocarcinoma (iCCA)
derives from expert centers. This study aimed to investigate the treatment and …